StockData
Castle Biosciences Inc logo

Castle Biosciences Inc (CSTL) income statement

CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/302% below fair value
$33.38+0.40 (+1.21%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield 0.00%

Castle Biosciences Inc income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
77.1%
Operating margin
-7.4%
Net margin
-6.1%
Return on equity, FY2025
-5.2%

Financial strength

Current ratio
5.28
Debt to equity
0.02
Debt to assets
1.7%
Cash to current liabilities
115.4%

Valuation

P/E ratio
–
Price to sales
2.70
Price to book
2.13
Dividend yield
0.00%

See a number that looks wrong?